FrancophonIA/ELRC3.0 huggingface dataset:
English: Renally eliminated medicinal products: Since emtricitabine and tenofovir are primarily eliminated by the kidneys, co-administration of Emtricitabine/Tenofovir disoproxil Krka with medicinal products that reduce renal function or compete for active tubular secretion (e.g. cidofovir) may increase serum concentrations of emtricitabine, tenofovir and/or the co-administered medicinal products.
Slovenian: Zdravila, ki se izločajo preko ledvic: Ker se emtricitabin in tenofovir izločata predvsem preko ledvic, sočasna uporaba zdravila Emtricitabin/dizoproksiltenofovirat Krka in zdravil, ki zmanjšujejo delovanje ledvic ali tekmujejo za aktivno tubularno sekrecijo (npr. cidofovir), lahko poveča serumske koncentracije emtricitabina, tenofovirja in/ali sočasno uporabljenih zdravil.
English: Limited clinical experience in patients co-infected with HIV and HBV suggests that treatment with emtricitabine or tenofovir disoproxil in antiretroviral combination therapy to control HIV infection results in a reduction in HBV DNA (3 log10 reduction or 4 to 5 log10 reduction, respectively) (see section 4.4).
Slovenian: Majhno število kliničnih izkušenj pri bolnikih, ki so hkrati okuženi z virusom HIV in HBV, kaže, da se zdravljenje z emtricitabinom ali dizoproksiltenofoviratom v kombinirani protiretrovirusni terapiji za nadzorovanje okužbe z virusom HIV odraža tudi v zmanjšanju HBV DNA (zmanjšanje 3 log10 pri emtricitabinu oz. 4 do 5 log10 pri dizoproksiltenofoviratu) (glejte poglavje 4.4).
English: The same recommendations apply as in adults (see Co-administration of other medicinal products below).
Slovenian: Sočasna uporaba in tveganje toksičnosti za ledvice Veljajo enaka priporočila kot pri odraslih (glejte spodnje poglavje Sočasno dajanje drugih zdravil).
English: If you are being treated for HIV infection your doctor will prescribe Emtricitabine/Tenofovir disoproxil Krka with other antiretroviral medicines.
Slovenian: - Če se zdravite zaradi okužbe s HIV, vam bo zdravnik predpisal zdravilo Emtricitabin/dizoproksiltenofovirat Krka skupaj z drugimi protiretrovirusnimi zdravili.
English: In 3 of 10 subjects who had acute HIV infection at study enrollment, M184I and M184V mutations were detected in the HIV of 2 of 2 subjects in the emtricitabine/tenofovir disoproxil group and 1 of 8 subjects in the placebo group.
Slovenian: Pri 3 od 10 oseb, ki so imele akutno okužbo s HIV ob vključitvi v študijo, so bile v HIV zaznane mutacije M184I in M184V pri 2 od 2 oseb v skupini, ki je prejemala emtricitabin/dizoproksiltenofovirat, in pri 1 od 8 oseb v skupini, ki je prejemala placebo.
English: Renal function (creatinine clearance and serum phosphate) should be evaluated prior to initiating emtricitabine/tenofovir for treatment of HIV-1 or for pre-exposure prophylaxis, and should be monitored during use as in adults (see above).
Slovenian: Ledvično funkcijo (očistek kreatinina in serumski fosfat) je treba pred uvedbo zdravila Emtricitabin/dizoproksiltenofovirat Krka za zdravljenje okužbe s HIV 1 ali zaščite pred izpostavitvijo, nato pa jih je treba med uporabo spremljati kot pri odraslih osebah (glejte zgoraj).
English: Lamivudine+ zidovudine+efavirenz
Slovenian: Lamivudin+ zidovudin+efavirenz
English: Emtricitabine/Tenofovir disoproxil Krka film coated tablets are blue, oval, biconvex tablets, of dimensions 20 mm x 10 mm.
Slovenian: Emtricitabin/dizoproksiltenofovirat Krka filmsko obložene tablete so modre, ovalne, bikonveksne; dimenzije: 20 mm x 10 mm.
English: Elderly: No dose adjustment is required (see section 5.2).
Slovenian: Posebne populacije Starostniki: Prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
English: Hepatic impairment: No dose adjustment is required in patients with hepatic impairment (see sections 4.4 and 5.2).
Slovenian: Jetrna okvara: Prilagoditev odmerka ni potrebna pri bolnikih z jetrno okvaro (glejte poglavji 4.4 in
English: If you take Emtricitabine/Tenofovir disoproxil Krka for treatment of HIV infection, stopping tablets may reduce the effectiveness of the anti-HIV therapy recommended by your doctor.
Slovenian: Če zdravilo Emtricitabin/dizoproksiltenofovirat Krka jemljete za zdravljenje okužbe s HIV, lahko prenehanje zdravljenja zmanjša učinkovitost zdravljenja okužbe s HIV, ki vam ga je predpisal zdravnik.
English: Tablet core: pregelatinized starch, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, sodium stearyl fumarate, stearic acid.
Slovenian: Jedro tablete: predgelirani škrob, premreženi natrijev karmelozat, laktoza monohidrat, mikrokristalna celuloza, natrijev stearilfumarat in stearinska kislina.
English: The Partners PrEP clinical study (CO-US-104-0380) evaluated emtricitabine/tenofovir disoproxil, tenofovir disoproxil 245 mg, or placebo in 4,758 HIV-uninfected subjects from Kenya or Uganda in serodiscordant heterosexual couples.
Slovenian: Klinična študija Partners PrEP (CO-US-104-0380) je ocenjevala emtricitabin/dizoproksiltenofovirat, dizoproksiltenofovirat 245 mg ali placebo pri 4.758 s HIV neokuženih osebah iz Kenije ali Ugande, ki so bili v serološko neskladnem heteroseksualnem partnerstvu.
English: Both emtricitabine triphosphate and tenofovir diphosphate are weak inhibitors of mammalian DNA polymerases and there was no evidence of toxicity to mitochondria in vitro and in vivo.
Slovenian: Emtricitabin trifosfat in tenofovir difosfat sta šibka zaviralca sesalske DNA-polimeraze; toksičnost za mitohondrije pri in vitro ali in vivo pogojih ni bila dokazana.
English: Co administration of sofosbuvir/velpatasvir with efavirenz-containing regimens is not recommended.
Slovenian: Sočasna uporaba sofosbuvirja/velpatasvirja z režimom zdravljenja z efavirenzom ni priporočena.
English: In vivo - treatment of HIV-1: In an open-label randomised clinical study (GS-01-934) in antiretroviralnaïve patients, genotyping was performed on plasma HIV-1 isolates from all patients with confirmed HIV RNA > 400 copies/mL at weeks 48, 96 or 144 or at the time of early study drug discontinuation.
Slovenian: Zdravljenje HIV-1 in vivo: V odprti, randomizirani klinični študiji (GS-01-934) pri bolnikih, še nezdravljenih s protiretrovirusnimi zdravili, je bila genotipizacija opravljena pri izolatih HIV-1 v plazmi vseh bolnikov s potrjenim HIV RNA > 400 kopij/ml v 48., 96. ali 144. tednu ali ob zgodnji prekinitvi jemanja študijskega zdravila.
English: During treatment for HIV there may be an increase in weight and in levels of blood lipids and glucose.
Slovenian: Med zdravljenjem okužbe z virusom HIV se lahko poveča telesna masa ter zviša koncentracija lipidov in glukoze v krvi.
English: Relative Risk Reduction (95% CI)
Slovenian: Relativno zmanjšanje tveganja (95-odstotni IZ)
English: In vivo -pre-exposure prophylaxis: Plasma samples from 2 clinical studies of HIV-1 uninfected subjects, iPrEx and Partners PrEP, were analysed for 4 HIV-1 variants expressing amino acid substitutions (i.e. K65R, K70E, M184V, and M184I) that potentially confer resistance to tenofovir or emtricitabine.
Slovenian: Zaščita pred izpostavitvijo in vivo: Vzorci plazme iz 2 kliničnih študij, iPrEx in Partners PrEP, pri osebah, ki niso bile okužene s HIV-1, so bili analizirani za 4 različice HIV-1 z izraženo substitucijo za aminokisline (tj. K65R, K70E, M184V in M184I), ki bi lahko povzročile rezistenco na tenofovir ali emtricitabin.
English: Renal impairment: Emtricitabine and tenofovir are eliminated by renal excretion and the exposure to emtricitabine and tenofovir increases in individuals with renal dysfunction (see sections 4.4 and 5.2).
Slovenian: Ledvična okvara: Emtricitabin in tenofovir se izločata skozi ledvice in pri posameznikih z ledvično disfunkcijo izpostavljenost emtricitabinu in tenofovirju naraste (glejte poglavji 4.4 in 5.2).
English: Baseline characteristics are summarised in Table 5.
Slovenian: Značilnosti populacije v izhodišču so povzete v preglednici 5.
English: If you notice within 12 hours of the time you usually take Emtricitabine/Tenofovir disoproxil Krka, take the tablet preferably with food as soon as possible.
Slovenian: - Če to opazite v roku 12 ur od časa, ko običajno vzamete zdravilo Emtricitabin/dizoproksiltenofovirat Krka, morate tableto vzeti čim prej, najbolje s hrano.
English: Clinical efficacy and safety of emtricitabine/tenofovir disoproxil was established from studies conducted with emtricitabine and tenofovir disoproxil when given as single agents.
Slovenian: Klinična učinkovitost in varnost emtricitabin/dizoproksiltenofovirata sta bili ugotovljeni v študijah, izvedenih z emtricitabinom in dizoproksiltenofoviratom, ko se uporabljata kot edino zdravilo.
English: Emtricitabine/Tenofovir disoproxil Krka can only help reduce your risk of getting HIV before you are infected.
Slovenian: Zdravilo Emtricitabin/dizoproksiltenofovirat Krka lahko samo pomaga zmanjšati tveganje za okužbo z virusom HIV, preden se okužite.
English: Bone problems (sometimes resulting in fractures) may also occur due to damage to kidney tubule cells (see section 4, Possible side effects).
Slovenian: Zaradi okvare celic ledvičnih tubulov se lahko pojavijo tudi težave s kostmi (včasih pride do zlomov) (glejte poglavje 4, Možni neželeni učinki).
English: Do not take Emtricitabine/Tenofovir disoproxil Krka to reduce your risk unless you are confirmed to be HIV negative.
Slovenian: Zdravila Emtricitabin/dizoproksiltenofovirat Krka ne jemljite za zmanjšanje tveganja, razen če je potrjeno, da ste HIV negativni.
English: Tests may also show: decreases in potassium in the blood increased creatinine in your blood changes to your urine
Slovenian: Preiskave lahko kažejo tudi: - zmanjšanje količine kalija v krvi - povišan kreatinin v krvi - spremembe urina
English: The bioequivalence of one emtricitabine/tenofovir disoproxil film-coated tablet with one emtricitabine 200 mg hard capsule and one tenofovir disoproxil 245 mg film-coated tablet was established following single dose administration to fasting healthy subjects.
Slovenian: Bioekvivalenca ene filmsko obložene tablete emtricitabina/dizoproksiltenofovirata z eno 200 mg trdo kapsulo emtricitabina in eno 245 mg filmsko obloženo tableto dizoproksiltenofovirata je bila ugotovljena po zaužitju enkratnega odmerka pri zdravih osebah na tešče.
English: Baseline characteristics are summarised in Table 8.
Slovenian: Značilnosti populacije ob izhodišču so povzete v preglednici 8.
English: Moderate renal impairment (CrCl 3049 mL/min)
Slovenian: Zmerna ledvična okvara (CrCl 30 - 49 ml/min)
English: Individuals with renal impairment: Since tenofovir disoproxil can cause renal toxicity, close monitoring of renal function is recommended in any adults with renal impairment receiving Emtricitabine/Tenofovir disoproxil Krka (see sections 4.2, 4.4 and 5.2).
Slovenian: Posamezniki z ledvično okvaro: Ker lahko dizoproksiltenofovirat povzroči ledvično toksičnost, se priporoča skrbno nadziranje ledvične funkcije pri vseh odraslih z ledvično okvaro, ki prejemajo zdravilo Emtricitabin/dizoproksiltenofovirat Krka (glejte poglavja 4.2, 4.4 in 5.2).
English: Tenofovir disoproxil should be avoided in patients with HIV1 harbouring the K65R mutation.
Slovenian: Uporabi dizoproksiltenofovirata se je potrebno izogniti pri bolnikih s HIV-1, nosilci mutacije K65R.
English: Treatment of HIV-1 infection in the paediatric population There are no clinical studies conducted with emtricitabine/tenofovir disoproxil in the paediatric population with HIV-1 infection.
Slovenian: Zdravljenje okužbe s HIV-1 pri pediatrični populaciji Kliničnih študij z emtricitabin/dizoproksiltenofoviratom pri pediatrični populaciji, okuženi s HIV-1, niso izvedli.
English: The rate of HIV-1 seroconversion in males was 0.24/100 person-years of emtricitabine/tenofovir disoproxil exposure and the rate of HIV-1 seroconversion in females was 0.95/100 person-years of emtricitabine/tenofovir disoproxil exposure.
Slovenian: Stopnja serokonverzije HIV-1 pri moških, ki so prejemali emtricitabin/dizoproksiltenofovirat, je bila 0,24/100 človek-let, stopnja serokonverzije HIV-1 pri ženskah, ki so prejemali emtricitabin/dizoproksiltenofovirat, pa je bila 0,95/100 človek-let.
English: - Emtricitabine/Tenofovir disoproxil Krka can be administered in place of emtricitabine and tenofovir disoproxil used separately at the same doses.
Slovenian: - Zdravilo Emtricitabin/dizoproksiltenofovirat Krka se lahko jemlje namesto emtricitabina in dizoproksiltenofovirata, ki se uporabljata ločeno v enakih odmerkih.
English: Emtricitabine/Tenofovir disoproxil Krka should only be used to reduce the risk of acquiring HIV-1 in individuals confirmed to be HIV negative (see section 4.3).
Slovenian: Zdravilo Emtricitabin/dizoproksiltenofovirat Krka se sme uporabljati samo za zmanjšanje tveganja za okužbo s HIV-1 pri posameznikih, ki so potrjeno HIV negativni (glejte poglavje 4.3).
English: Co-administration of tenofovir disoproxil and didanosine:
Slovenian: Sočasna uporaba dizoproksiltenofovirata in didanozina:
English: Assessment of adverse reactions related to tenofovir disoproxil is based on two randomised trials (studies GS-US-104-0321 and GS-US-104-0352) in 184 HIV 1 infected paediatric patients (aged 2 to < 18 years) who received treatment with tenofovir disoproxil (n = 93) or placebo/active comparator (n = 91) in combination with other antiretroviral agents for 48 weeks (see section 5.1).
Slovenian: Ocena neželenih učinkov, povezanih z dizoproksiltenofoviratom, temelji na dveh randomiziranih preskušanjih (študiji GS-US-104-0321 in GS-US-104-0352) pri 184 pediatričnih bolnikih, okuženih s HIV-1 (starih od 2 do < 18 let), ki so 48 tednov prejemali dizoproksiltenofovirat (n = 93) ali placebo/aktivno primerjavo (n = 91) v kombinaciji z drugimi protiretrovirusnimi zdravili (glejte poglavje 5.1).
English: If bone abnormalities are detected or suspected during use of emtricitabine/tenofovir in any paediatric patients, consultation with an endocrinologist and/or nephrologist should be obtained.
Slovenian: Ob odkritju kostnih nenormalnosti ali sumu nanje med uporabo zdravila Emtricitabin/dizoproksiltenofovirat Krka pri katerem koli pediatričnem bolniku se je treba posvetovati z endokrinologom in/ali nefrologom.
English: In order to optimise the absorption of tenofovir, it is recommended that Emtricitabine/Tenofovir disoproxil Krka should preferably be taken with food.
Slovenian: Za optimalno absorpcijo tenofovirja se priporoča zdravilo Emtricitabin/dizoproksiltenofovirat Krka jemati s hrano.
English: 'Case' = HIV seroconverter; 'Cohort' = 100 randomly selected subjects from each of the tenofovir disoproxil 245 mg and emtricitabine/tenofovir disoproxil groups.
Slovenian: "Študijska skupina" = serokonverter HIV; "podskupina" = 100 naključno izbranih oseb iz vsake od skupin, ki so prejemale dizoproksiltenofovirat 245 mg in ki prejemajo emtricitabin/dizoproksiltenofovirat.
English: Emtricitabine/Tenofovir disoproxil Krka is used to treat Human Immunodeficiency Virus 1 (HIV-1) infection in adults.
Slovenian: - Zdravilo Emtricitabin/dizoproksiltenofovirat Krka se uporablja za zdravljenje okužbe z virusom HIV-1 (virus človeške imunske pomanjkljivosti 1) pri odraslih.
English: Each film-coated tablet contains 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300.7 mg of tenofovir disoproxil succinate or 136 mg of tenofovir).
Slovenian: Ena filmsko obložena tableta vsebuje 200 mg emtricitabina in 245 mg dizoproksiltenofovirata (kar ustreza 300,7 mg dizoproksiltenofovirijevega sukcinata ali 136 mg tenofovirja).
English: Emtricitabine/Tenofovir disoproxil Krka is not recommended if you have severe kidney disease or are on dialysis.
Slovenian: Uporaba zdravila Emtricitabin/dizoproksiltenofovirat Krka ni priporočljiva, če imate hudo ledvično obolenje ali ste na dializi.
English: If you feel dizzy while taking Emtricitabine/Tenofovir disoproxil Krka, do not drive and do not use any tools or machines.
Slovenian: Če se vam v času zdravljenja z zdravilom Emtricitabin/dizoproksiltenofovirat Krka pojavlja omotičnost, ne vozite avtomobila in ne upravljajte z orodji ali stroji.
English: Blood and lymphatic system disorders: Common:
Slovenian: Bolezni krvi in limfatičnega sistema: Pogosto:
English: In 2 of 14 subjects who had acute HIV infection at study enrollment, the K65R mutation was detected in the HIV of 1 of 5 subjects in the tenofovir disoproxil 245 mg group and the M184V mutation (associated with resistance to emtricitabine) was detected in the HIV of 1 of 3 subjects in the emtricitabine/tenofovir disoproxil group
Slovenian: Pri 2 od 14 oseb, ki so imele akutno okužbo s HIV ob vključitvi v študijo, je bila v HIV zaznana mutacija K65R pri 1 od 5 oseb v skupini, ki je prejemala dizoproksiltenofovirat 245 mg in zaznana je bila mutacija M184V (povezana z rezistenco na emtricitabin) pri 1 od 3 oseb v skupini, ki je prejemala emtricitabin/dizoproksiltenofovirat.
English: Please refer to the patient information leaflets of the other antiretrovirals for guidance on how to take those medicines.
Slovenian: Prosimo, preberite si navodila za uporabo drugih protiretrovirusnih zdravil.
English: Take Emtricitabine/Tenofovir disoproxil Krka every day to reduce your risk, not just when you think you have been at risk of HIV infection.
Slovenian: - Zdravilo Emtricitabin/dizoproksiltenofovirat Krka vzemite vsak dan za zmanjšanje tveganja in ne le takrat, ko menite, da obstaja tveganje za okužbo z virusom HIV.
English: The mean changes in CD4 cell count from baseline were +185 cells/mm
Slovenian: Srednje spremembe števila celic CD4 so bile od izhodišča +185 celic/mm3 in +196 celic/mm3.
English: At week 48, 83% of patients in the tenofovir disoproxil treatment group and 92% of patients in the stavudine or zidovudine treatment group had HIV 1 RNA concentrations < 400 copies/mL.
Slovenian: V 48. tednu je 83 % bolnikov v skupini, zdravljeni z dizoproksiltenofoviratom, in 92 % bolnikov v skupini, zdravljeni s stavudinom ali zidovudinom, imelo koncentracije HIV-1 RNA < 400 kopij/ml.
English: The potential renal and bone effects with long-term use of emtricitabine/tenofovir for preexposure prophylaxis in adolescents are unknown (see section 4.4).
Slovenian: Možnost učinkov na ledvice in kosti pri dolgoročni uporabi emtricitabina/dizoproksiltenofovirata za zaščito pred izpostavitvijo pri mladostnikih ni znana (glejte poglavje 4.4).
English: Limited pharmacokinetic data are available for emtricitabine and tenofovir after co-administration of separate preparations or as emtricitabine/tenofovir disoproxil in patients with renal impairment.
Slovenian: Na voljo je malo farmakokinetičnih podatkov za emtricitabin in tenofovir po sočasnem jemanju posameznih pripravkov ali v obliki fiksne kombinacije emtricitabina/dizoproksiltenofovirata pri bolnikih z ledvično okvaro.
English: Bone problems.
Slovenian: - Težave s kostmi.
English: What Emtricitabine/Tenofovir disoproxil Krka looks like and contents of the pack Emtricitabine/Tenofovir disoproxil Krka film coated tablets (tablets) are blue, oval, biconvex tablets, of dimensions 20 mm x 10 mm.
Slovenian: Izgled zdravila Emtricitabin/dizoproksiltenofovirat Krka in vsebina pakiranja Emtricitabin/dizoproksiltenofovirat Krka filmsko obložene tablete (tableta) so modre, ovalne, bikonveksne; dimenzije: 20 mm x 10 mm.
English: - That a multidisciplinary approach is recommended for the management of paediatric patients - That there is an increased risk of renal disease in HIV infected patients associated with tenofovir disoproxil-containing products such as Emtricitabine/Tenofovir disoproxil Krka - That Emtricitabine/Tenofovir disoproxil Krka is not recommended for use in paediatric patients with renal impairment - That use of Emtricitabine/Tenofovir disoproxil Krka should be avoided with concomitant or recent use of nephrotoxic medicinal products.
Slovenian: - da se za vodenje pediatričnih bolnikov priporoča multidisciplinarni pristop; - da obstaja povečano tveganje za ledvično bolezen pri bolnikih s HIV, povezano z zdravili, ki vsebujejo dizoproksiltenofovirat, kot je zdravilo Emtricitabine/Tenofovir disoproxil Krka; - da se zdravila Emtricitabine/Tenofovir disoproxil Krka pri pediatričnih bolnikih z ledvično okvaro ne priporoča; - da se je treba uporabi zdravila Emtricitabine/Tenofovir disoproxil Krka izogniti, če bolnik sočasno jemlje ali je predhodno jemal nefrotoksična zdravila.
English: Stopping use of Emtricitabine/Tenofovir disoproxil Krka, or missing doses, may increase your risk of getting HIV infection.
Slovenian: Prenehanje uporabe zdravila Emtricitabin/dizoproksiltenofovirat Krka ali izpuščeni odmerki lahko povečajo tveganje za pridobitev okužbe s HIV.
English: Pack sizes: 30 film coated tablets (1x30) and 90 film-coated tablets (3x30).
Slovenian: Velikost pakiranj: 30 filmsko obloženih tablet (1 x 30) in 90 filmsko obloženih tablet (3 x 30)
English: HIV-1 infected patients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Slovenian: Pri bolnikih, okuženih s HIV-1, s kroničnim hepatitisom B ali C, ki se zdravijo s protiretrovirusno terapijo, obstaja povečano tveganje za hude in potencialno usodne neželene učinke na delovanje jeter.
English: Paediatric population: The safety and efficacy of emtricitabine/tenofovir disoproxil in children under the age of 12 years have not been established (see section 5.2).
Slovenian: Varnost in učinkovitost emtricitabina/dizoproksiltenofovirata pri otrocih, mlajših od 12 let, nista bili dokazani (glejte poglavje 5.2).
English: However, individuals should be informed that dizziness has been reported during treatment with both emtricitabine and tenofovir disoproxil.
Slovenian: Prejemnike je kljub temu potrebno opozoriti, da se lahko v času zdravljenja z emtricitabinom in dizoproksiltenofoviratom pojavi omotičnost.
English: If a dose of Emtricitabine/Tenofovir disoproxil Krka is missed within 12 hours of the time it is usually taken, Emtricitabine/Tenofovir disoproxil Krka should be taken as soon as possible and the normal dosing schedule should be resumed.
Slovenian: Če se izpusti odmerek zdravila Emtricitabin/dizoproksiltenofovirat Krka v roku 12 ur od časa, ko se ga običajno vzame, je treba vzeti zdravilo Emtricitabin/dizoproksiltenofovirat Krka takoj, ko je mogoče, nato pa nadaljevati z običajnim režimom odmerjanja.
English: While taking Emtricitabine/Tenofovir disoproxil Krka you may still develop infections or other illnesses associated with HIV infection.
Slovenian: Med jemanjem zdravila Emtricitabin/dizoproksiltenofovirat Krka lahko še vedno pride do okužbe ali drugih bolezni, povezanih z okužbo s HIV.
English: If you are taking Emtricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV, do not stop taking Emtricitabine/Tenofovir disoproxil Krka or miss any doses.
Slovenian: Če zdravilo Emtricitabin/dizoproksiltenofovirat Krka jemljete za zmanjšanje tveganja za okužbo s HIV, ne prenehajte jemati zdravila Emtricitabin/dizoproksiltenofovirat Krka in ne izpustite nobenega odmerka.
English: HIV-1 infected patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice.
Slovenian: Bolniki s HIV-1, s preeksistentno okrnjeno funkcijo jeter, vključno s kroničnim aktivnim hepatitisom, imajo v času kombinirane protiretrovirusne terapije (combination antiretroviral therapy, CART) več motenj v delovanju jeter.
English: The following may be signs of lactic acidosis: deep rapid breathing drowsiness feeling sick (nausea), being sick (vomiting) stomach pain
Slovenian: Naslednji znaki lahko kažejo na laktacidozo: - globoko, hitro dihanje - zaspanost
English: Whenever possible, Emtricitabine/Tenofovir disoproxil Krka should be taken with food.
Slovenian: - Kadar je mogoče, je treba zdravilo Emtricitabin/dizoproksiltenofovirat Krka jemati s hrano.